U.S. Markets open in 5 hrs 43 mins

Incyte Jakafi label update expected, says UBS

UBS said new label dosing information updated for Jakafi was expected along with language around PML risk. The firm does not see any significant impact from the revisions and reiterates is Buy rating and $27 price target.